Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
Graninger, W; Smolen, J.
Treatment of rheumatoid arthritis by TNF-blocking agents.
Int Arch Allergy Immunol. 2002; 127(1):10-14
Doi: 10.1159/000048164
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Graninger Winfried
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Chimeric, humanized and fully human monoclonal antibodies directed against tumor necrosis factor-alpha as well as TNF receptor constructs can be administered relatively safely during long-term use for the treatment of rheumatoid arthritis (RA). Their therapeutic efficacy in patients refractory to treatment with conventional disease-modifying drugs was proven in large clinical trials and their ability to slow the progression of disease was demonstrated radiographically. The insights into the pathophysiology of RA provided by the beneficial effects of blocking proinflammatory cytokines will lead to further drug development for this destructive autoimmune disease.
- Find related publications in this database (using NLM MeSH Indexing)
- Animals -
- Antibodies, Monoclonal - therapeutic use
- Antirheumatic Agents - therapeutic use
- Arthritis, Rheumatoid - drug therapy
- Humans - drug therapy
- Immunoglobulin G - therapeutic use
- Mice - therapeutic use
- Receptors, Tumor Necrosis Factor - therapeutic use
- Tumor Necrosis Factor-alpha - antagonists and inhibitors
- Find related publications in this database (Keywords)
- rheumatoid arthritis
- treatment
- tumor necrosis factor-alpha
- monoclonal antibody
- infliximab
- etanercept
- cytokine blockade
- disease-modifying drug